4/14 RegenMD

RegenMD         Use of Dip Pen Nanolithography to Produce Micropatterned ... April 13, 2011 at 11:55 PM   The placing of cells at defined locations on a substrate is vital in the development of cell-based sensors, cell biology research and tissue engineering ... AZoNano.com         Organogenesis expanding in Canton April 13, 2011 at 7:35 PM   The company, which makes regenerative medicine therapies to speed healing, has grown steadily in recent years, adding to its office campus with financial help from the state. The campus will ultimately include four buildings with 330000 square feet of ... See all stories on this topic »         Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely ... April 13, 2011 at 5:42 PM   In their pioneering work, a team of researchers led by Dr. Shaf Keshavjee, Senior Scientist at the McEwen Centre for Regenerative Medicine, University Health Network (UHN), Director of the Toronto Lung Transplant Program, Toronto General Hospital, ... See all stories on this topic »         Organogenesis, Life Sciences Center Break Ground on World's Largest Automated ... April 13, 2011 at 5:42 PM   Organogenesis kicked off the celebration by announcing that it has selected Cambridge-based SMMA/Symmes Maini & McKee Associates as the architect and CRB Consulting Engineers, Inc. as the engineer for the state-of-the-art regenerative medicine ... See all stories on this topic »         ALS Canada and ALS Nova Scotia Celebrate Walking Towards a Cure for ALS April 13, 2011 at 1:34 PM   He was granted $100000 to study whether induced pluripotent stem (iPS) cells are a viable model system for studying sporadic ALS and if they could be used to treat ALS patients in a regenerative medicine approach. He also received a Neuromuscular ... See all stories on this topic »         Retinal regeneration a step closer April 13, 2011 at 10:43 AM   The finding may have important implications for regenerative medicine for those suffering from retinal degenerative disorders. Researchers added extracellular matrix proteins to serum-free culture of embryoid body-like aggregates (SFEBq) medium, ... See all stories on this topic » LabnewsOnline         "The Ultrasound Market Outlook to 2016" and Other New Reports by Business ... April 13, 2011 at 10:43 AM   Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a "tipping point", after which no medical industry players will want to be left behind. ... See all stories on this topic »         "The Ultrasound Market Outlook to 2016" and Other New Reports by ... April 13, 2011 at 10:07 AM   The study covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, ...         New evidence that chronic ulcerative stomatitis is an autoimmune ... April 13, 2011 at 9:45 AM   Garlick is also the director of the Center for Integrated Tissue Engineering (CITE) at Tufts University School of Dental Medicine, which is dedicated to ...         Advances in translational research in neuromuscular diseases. April 13, 2011 at 8:13 AM   Advances in translational research in neuromuscular diseases. Arch Neurol. 2011 Apr;68(4):429-33 Authors: Pleasure D New therapies developed over the past 3 years for previously intractable diseases of skeletal muscle, neuromuscular junctions, peripheral nerves, and motor neurons are now being incorporated into our standard neuromuscular clinical practice. The past 3 years were also marked by important advances in our understanding of the pathogenesis and pathophysiology of inherited and acquired neuromuscular diseases; these advances were acquired by the use of high-throughput nucleotide and protein analytic methods, novel animal models, and human-induced pluripotent stem cell-derived "diseases in a dish." Over the next decade, we can reasonably anticipate that these insights, coupled with advances in our ability to modulate immune mechanisms, to modify the activity of mutant genes, and to perform gene replacement therapies with enhanced viral vector-based and stem cell-based delivery systems, will revolutionize our management of neuromuscular diseases. PMID: 21482923 [PubMed - in process]         Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. April 13, 2011 at 8:13 AM   Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet. 2011 Apr 2;377(9772):1175-82 Authors: Raya-Rivera A, Esquiliano DR, Yoo JJ, Lopez-Bayghen E, Soker S, Atala A Complex urethral problems can occur as a result of injury, disease, or congenital defects and treatment options are often limited. Urethras, similar to other long tubularised tissues, can stricture after reconstruction. We aimed to assess the effectiveness of tissue-engineered urethras using patients' own cells in patients who needed urethral reconstruction. PMID: 21388673 [PubMed - indexed for MEDLINE]         Organogenesis to Mass. produce human cells April 13, 2011 at 1:24 AM   Organogenesis Inc. — a pioneer in the regenerative medicine field that spun out of MIT — this morning is heralding the construction of a $63 million, 95000-square-foot center on its Canton campus. It will also announce plans to buy another nearby ... See all stories on this topic »             This email was sent to regenmd@gmail.com. Delivered by Feed My Inbox PO Box 682532 Franklin, TN 37068 Account Login Unsubscribe Here